Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized ...

The pharma giant may be heading for a new era of growth. In later stages of the pandemic, sales of coronavirus products flagged. To add to this bad news, investors focused on upcoming patent ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

J&J’s biggest strength is its diversified business model, which helps it to withstand economic cycles more effectively. It operates through more than 275 subsidiaries. J&J’s Innovative Medicine unit ...